|
Video: What is a Stock Split?
|
|
MaxCyte is a commercial cell engineering company engaged on providing enabling platform technologies to improve cell-based research and development as well as cell therapeutic discovery, development and commercialization. Co.'s ExPERT platform, which is based on its Flow Electroporation technology, has been designed to address this cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of cell-based medicines. The ExPERT family of products includes: three instruments, which Co. calls the ATx, STx and GTx. According to our MaxCyte stock split history records, MaxCyte has had 0 splits. | |
|
MaxCyte (MXCT) has 0 splits in our MaxCyte stock split history database.
Looking at the MaxCyte stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into MaxCyte shares, starting with a $10,000 purchase of MXCT, presented on a split-history-adjusted basis factoring in the complete MaxCyte stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
08/02/2021 |
|
End date: |
04/19/2024 |
|
Start price/share: |
$16.50 |
|
End price/share: |
$3.95 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-76.06% |
|
Average Annual Total Return: |
-40.94% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$2,393.57 |
|
Years: |
2.72 |
|
|
|
|
|